Newsroom
Category
July 12, 2022
Black women die of breast cancer at rates nearly 40% higher than white women, despite having lower instances of the disease, because of racial disparities in care, according to a New England Journal of Medicine article by a UT Health San Antonio surgical oncologist and two American Cancer Society scientists. The authors, led by Ismail […]
July 12, 2022
Note: This article was produced and contributed by Joel Williams and Julie Collins. The first therapy to be developed specifically for post-traumatic headache significantly reduced related disability in veterans following a traumatic brain injury (TBI). It also reduced co-occurring symptoms of post-traumatic stress disorder (PTSD) comparably to a gold-standard PTSD treatment. Moreover, the innovative treatment, […]
June 27, 2022
In December 2018, UT Health San Antonio received approval from its accrediting organization, the Southern Association of Colleges and Schools Commission on Colleges, to develop institutional infrastructure through which to advance interprofessional education (IPE) and collaboration across all five schools. The university’s accelerated progress in this domain has led to a national award from the […]
June 27, 2022
The Dialysis Doggos are part of a research study being conducted by Meredith L. Stensland, PhD, LMSW, assistant professor of research in the Department of Psychiatry and Behavioral Sciences. The study investigates the effect of an animal assisted intervention for patients receiving dialysis, and if this intervention improves symptoms of pain and depression and reduces the number of skipped dialysis treatment sessions.
June 17, 2022
In a special section of the June 17, 2022, San Antonio Business Journal, experts from Mays Cancer Center at UT Health San Antonio discuss the broad scope of cancer patient care and lifesaving research taking place daily at the center and its value to the local community and regional economy.
June 17, 2022
An experimental brain injury medication conceived in laboratories at UT Health San Antonio was tested Tuesday, June 14, in the first human subject. If the drug, called AST-004, performs well in human studies, it will be an urgently needed and novel treatment for stroke and traumatic brain injury victims, including those with concussions.
